ColoSense is the first noninvasive colorectal cancer screening test to offer a view of disease activity through RNA biomarkers, according to a May 6 news release from Geneoscopy.
The company is working with payers, professional societies, and advocacy partners to support a commercial launch later this year or early in 2025, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
